Safety, Tolerability, and Efficacy of 24 Weeks Simeprevir+Sofosbuvir for Chronic Hepatitis C Genotype 1
Status:
Withdrawn
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
The goal of this pilot study is to examine both efficacy and tolerability in patients with
HCV genotype 1 and mild decompensation with Child-Pugh-Turcott score of 6 or lower. The CPT
score is used to assess the prognosis of chronic liver diseases, as well as the required
strength and treatment and necessity of liver transplantation. A higher CPT score denotes
higher necessity of liver transplantation.